HELEN SCOTT-BAYLEY: Open Payments
NPI 1316599145 · ELLICOTT CITY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$336 in 14 payments from 9 companies in 2025. Trend: 2023 $310 · 2024 $163 · 2025 $336
Food & beverage: $336
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $130 |
| Lilly USA, LLC | 2 | $52 |
| Novo Nordisk Inc | 2 | $41 |
| Dexcom, Inc. | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Exact Sciences Corporation | 1 | $16 |
| Gilead Sciences, Inc. | 1 | $15 |
Products named: INGREZZA, MOUNJARO, DEXCOM G7 GSS (161), Ozempic, FARXIGA, CAPLYTA, Rybelsus, Kerendia.
Industry payments across MD — which companies pay providers there.
